JP2016530265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530265A5 JP2016530265A5 JP2016534801A JP2016534801A JP2016530265A5 JP 2016530265 A5 JP2016530265 A5 JP 2016530265A5 JP 2016534801 A JP2016534801 A JP 2016534801A JP 2016534801 A JP2016534801 A JP 2016534801A JP 2016530265 A5 JP2016530265 A5 JP 2016530265A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- methylumbelliferone
- disease
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 47
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 claims description 31
- 210000003289 regulatory T cell Anatomy 0.000 claims description 16
- 208000012657 Atopic disease Diseases 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 208000026935 allergic disease Diseases 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 102000016354 Glucuronosyltransferase Human genes 0.000 claims description 9
- 108010092364 Glucuronosyltransferase Proteins 0.000 claims description 9
- 229940123064 Glycosyl transferase inhibitor Drugs 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000003297 glycosyltransferase inhibitor Substances 0.000 claims description 9
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 9
- 229940099552 hyaluronan Drugs 0.000 claims description 9
- 229920002674 hyaluronan Polymers 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- 230000005867 T cell response Effects 0.000 claims description 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 8
- ARQXEQLMMNGFDU-JHZZJYKESA-N 4-methylumbelliferone beta-D-glucuronide Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ARQXEQLMMNGFDU-JHZZJYKESA-N 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000016192 Demyelinating disease Diseases 0.000 claims description 3
- 206010012305 Demyelination Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 30
- 230000001939 inductive effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361865084P | 2013-08-12 | 2013-08-12 | |
| US61/865,084 | 2013-08-12 | ||
| PCT/US2014/050770 WO2015023691A2 (en) | 2013-08-12 | 2014-08-12 | 4-methylumbelliferone treatment for immune modulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019095974A Division JP2019135262A (ja) | 2013-08-12 | 2019-05-22 | 免疫調節のための４−メチルウンベリフェロン処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016530265A JP2016530265A (ja) | 2016-09-29 |
| JP2016530265A5 true JP2016530265A5 (enExample) | 2017-09-14 |
Family
ID=52468796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534801A Withdrawn JP2016530265A (ja) | 2013-08-12 | 2014-08-12 | 免疫調節のための４−メチルウンベリフェロン処置 |
| JP2019095974A Pending JP2019135262A (ja) | 2013-08-12 | 2019-05-22 | 免疫調節のための４−メチルウンベリフェロン処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019095974A Pending JP2019135262A (ja) | 2013-08-12 | 2019-05-22 | 免疫調節のための４−メチルウンベリフェロン処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10285976B2 (enExample) |
| EP (1) | EP3033416A4 (enExample) |
| JP (2) | JP2016530265A (enExample) |
| CN (1) | CN105579578A (enExample) |
| WO (1) | WO2015023691A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9833614B1 (en) | 2012-06-22 | 2017-12-05 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
| CA2988306A1 (en) | 2015-06-05 | 2016-12-08 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| WO2017213268A1 (ja) * | 2016-06-10 | 2017-12-14 | 国立大学法人東北大学 | インスリン分泌促進剤又はインスリン抵抗性改善剤 |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| US11278518B2 (en) | 2017-01-13 | 2022-03-22 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treatment using 4-methylumbelliferone and derivatives thereof |
| US10370400B2 (en) * | 2017-01-13 | 2019-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | 4-methylumbelliferone derivatives for treatment for immune modulation |
| WO2019165319A1 (en) * | 2018-02-23 | 2019-08-29 | The Board Of Trustees Of The Leland Stanford Junior University | The use of 4-methylumbelliferone to prevent immune rejection in cases of tissue transplantation |
| CA3095480A1 (en) * | 2018-03-29 | 2019-10-03 | Nevro Corp. | Therapeutic modulation to treat blood glucose abnormalities, including type 2 diabetes, and/or reduce hba1c levels, and associated systems and methods |
| EP3897620A4 (en) * | 2018-12-20 | 2022-08-24 | The Board of Trustees of the Leland Stanford Junior University | 4-METHYLUMBELLIFERYL GLUCURONIDE FOR INHIBITION OF HYALURONAN SYNTHESIS |
| WO2021078991A1 (en) * | 2019-10-25 | 2021-04-29 | Jessica Kwok | Treatment of conditions of the nervous system |
| EP4106737A4 (en) * | 2020-04-03 | 2023-08-02 | Standard of Care Corporation | HYALURONIDASE AND/OR 4-METHYLUMBELLIFERONE AEROSOL COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING DISEASES OR RESPIRATORY DISORDERS |
| CN114425050A (zh) * | 2022-02-09 | 2022-05-03 | 深圳大学 | 一种4-甲基伞形酮在制备抗过敏药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4451933B2 (ja) | 1996-12-27 | 2010-04-14 | 住友化学株式会社 | 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法 |
| GB9722600D0 (en) * | 1997-10-24 | 1997-12-24 | Bio Monde Holdings Internation | Pharmaceutical compositon |
| ATE378421T1 (de) | 1999-05-24 | 2007-11-15 | Abaron Biosciences Inc | Glycosyltransferase inhibitoren |
| JP2004517030A (ja) * | 1999-05-24 | 2004-06-10 | アバロン バイオサイエンシーズ， インコーポレイテッド | グリコシルトランスフェラーゼインヒビター |
| GB0205022D0 (en) * | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
| CA2486302A1 (en) * | 2002-05-17 | 2003-11-27 | Faust Pharmaceuticals | Methods for the prevention and/or the treatment of neurological disorders |
| WO2004082610A2 (en) * | 2003-03-14 | 2004-09-30 | Brigham And Women's Hospital, Inc. | Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders |
| WO2005013947A2 (en) | 2003-07-29 | 2005-02-17 | Universitätsklinikum Münster | Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer |
| US20120219506A1 (en) * | 2009-11-05 | 2012-08-30 | Sloan Kettering Institute For Cancer Research | Catenae: Serosal Cancer Stem Cells |
| MX348420B (es) * | 2010-07-20 | 2017-06-12 | Halozyme Inc | Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios. |
| NZ700073A (en) * | 2012-04-04 | 2016-08-26 | Halozyme Inc | Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane |
| CN102846598A (zh) | 2012-08-03 | 2013-01-02 | 广州康臣药物研究有限公司 | 香豆素在制备AGEs形成抑制剂中的应用 |
-
2014
- 2014-08-12 EP EP14836423.5A patent/EP3033416A4/en not_active Withdrawn
- 2014-08-12 US US14/911,533 patent/US10285976B2/en active Active
- 2014-08-12 CN CN201480053371.4A patent/CN105579578A/zh active Pending
- 2014-08-12 WO PCT/US2014/050770 patent/WO2015023691A2/en not_active Ceased
- 2014-08-12 JP JP2016534801A patent/JP2016530265A/ja not_active Withdrawn
-
2019
- 2019-05-03 US US16/403,293 patent/US20200101042A1/en not_active Abandoned
- 2019-05-22 JP JP2019095974A patent/JP2019135262A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019135262A5 (enExample) | ||
| Wyllie et al. | European Resuscitation Council Guidelines for Resuscitation 2015: Section 7. Resuscitation and support of transition of babies at birth | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| SA519402217B1 (ar) | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون | |
| MX2015004565A (es) | Metodo y dispositivo para conmutacion de camaras. | |
| JP2019516739A5 (enExample) | ||
| RU2017112747A (ru) | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции | |
| MA43404A (fr) | Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques | |
| JP2016163571A5 (enExample) | ||
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| EA201591379A1 (ru) | Липопротеин-ассоциированные ингибиторы фосфолипазы a2 (lp-pla) на основе 2,3-дигидроимидазо[1,2-с]пиримидин-5(1h)-онов | |
| JP2016516074A5 (enExample) | ||
| WO2014058979A8 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2016539156A5 (enExample) | ||
| CA3015494C (en) | Novel compositions and therapeutic methods | |
| CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
| EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2017533220A5 (enExample) | ||
| EA201492097A1 (ru) | 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1 | |
| EA201590066A1 (ru) | Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1 | |
| EA202091308A1 (ru) | Модифицированный вакцинный штамм brucella для лечения бруцеллеза | |
| EP2676665A4 (en) | USE OF ALPHA-MANGOSTINE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER |